The Phase 3 study evaluating plozasiran for adults with hypertriglyceridemia reached its primary completion on 2026-06-01. This milestone indicates that the main data collection for the trial has concluded, with results anticipated in the future.
The trial, identified as NCT06347133, is assessing the safety and efficacy of plozasiran injection.
Background
Hypertriglyceridemia (HTG) is a condition characterized by elevated levels of triglycerides in the blood, which can contribute to various health risks. Plozasiran (also known as ARO-APOC3) is being investigated as a potential therapeutic option for managing this condition.
Trial design
This was a Phase 3, randomized study (NCT06347133) titled "Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia." The trial enrolled 1,456 adult participants diagnosed with hypertriglyceridemia. Participants were randomized to receive either plozasiran injection or placebo over four doses, administered once every three months, to evaluate its efficacy and safety profile.
What this means
The primary completion of the Phase 3 study for plozasiran in hypertriglyceridemia marks a significant step towards understanding its potential role in treatment. While specific efficacy and safety results are not yet available, this completion signals that the comprehensive data required for analysis has been gathered. The findings from this large-scale trial will be crucial for determining the future of plozasiran as a therapeutic option for patients with elevated triglyceride levels.
Source
The primary completion status for the trial was updated on 2026-06-01 on ClinicalTrials.gov, an official database of clinical studies. The full details of the study are available on clinicaltrials.gov under the identifier NCT06347133.